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Abstract Many behavioral interventions, whether for the
management of chronic pain, overeating, medication adher-
ence, or substance abuse, are ineffective outside of the clinic
or office environments in which they are taught. This lack of
utility has spawned interest in enabling technologies that are
capable of detecting changes in affective state that potentially
herald a transition to risky behaviors. We have therefore
undertaken the preliminary development of “iHeal”, an inno-
vative constellation of technologies that incorporates artificial
intelligence, continuous biophysical monitoring, wireless con-
nectivity, and smartphone computation. In its fully realized
form, iHeal can detect developing drug cravings; as a multi-
media device, it can also intervene as the cravings develop to
prevent drug use. This manuscript describes preliminary data
related to the iHeal Project and our experience with its use.
Keywords Drug abuse . mHealth . eHealth .Wireless
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Introduction
Behavioral modification interventions often fail in natural
environments because patients have difficulty enacting them
outside of the controlled setting of a clinic or office in which
they are taught [1]. One reason for this failure is that patients
neither detect biological and affective changes that herald
increased risk, nor do they modify behaviors in a way that
decreases health risk [1]. The shortcomings of behavioral
interventions have spawned interest in technologies that are
capable of detecting changes in affective state that herald
transitions to risky behaviors such as substance use [1]. We
have therefore initiated a series of efforts to develop
“iHeal”, an innovative constellation of technologies that
incorporate artificial intelligence, continuous biophysical
monitoring, wireless connectivity, and smartphone computation.
iHeal works in the following way (Fig. 1). Individuals
with histories of substance abuse and PTSD wear a sensor
band that measure electrodermal activity, body motion, skin
temperature and, optionally, heart rate, each of which pro-
vides a measure of sympathetic nervous system activity due
to arousal or stress [2]. The sensor band wirelessly transmits
information to the smartphone, where a mobile software
application monitors and processes the user’s physiology
data. When the software detects an increased level of sym-
pathetic nervous system activity, iHeal assesses ecological
and behavioral events surrounding the change in physiolo-
gy. The assessment is simple and involves the iHeal soft-
ware asking the user to annotate events by self-reporting
affect, level of stress, drug cravings, activities, among other
items. Collectively, these data—skin conductance, tempera-
ture, motion, time, location, and annotations—comprise a
dataset that is used to train a machine learning algorithm to
recognize behavioral transitions. The trained algorithm is
downloaded onto the smartphone and the process repeated,
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with iterative periods of data collection, testing, and retrain-
ing improving the predictive ability of iHeal’s algorithm.
The ultimate goal of iHeal is to identify in real-time drug
cravings and deliver personalized, multimedia drug preven-
tion interventions precisely at the moment of greatest need.
While we ultimately hope to identify active drug craving
and use from antecedent affective changes, iHeal requires a
form factor that is highly acceptable to potential study
populations. We therefore describe in this manuscript our
preliminary efforts related to the iHeal Project and improving
experience with its use: system architecture, identification of
acceptable form factors, data encryption, and attrition of
devices.
Methods
The Institutional Review Boards of every participating in-
stitution approved all phases of this study; all participants
provided written informed consent and were compensated
for their participation. We used a design approach to the
iHeal Project; whereas the scientific method is analytic and
grounded in hypotheses, a design approach is constructive
[3, 4]. Accordingly, we generated a system architecture for
the iHeal Project that allows for (1) continuous detection of
skin conductance, skin temperature, motion, and pulse; (2)
machine learning software to identify when changes in
physiology (e.g., increased pulse/skin conductance and mo-
tion) potentially arose from changes in sympathetic tone (as
from drug craving and PTSD) rather than from exertion; (3)
real-time annotations by users of affective states and activities
in the time preceding drug use or cravings; and (4) a means to
iteratively improve the ability of the machine learning pro-
gram to identify craving/use episodes.
Once we had created the system architecture, we con-
ducted a focus group to identify the preferred structure of
the iHeal sensors and other operational features. We
recruited patients at the Edith Nourse Rogers Veterans Ad-
ministration Medical Center Domiciliary, a residential drug
treatment unit. Using a combination of flyers and in-person
presentations at community meetings, we sought to recruit
Operation Iraqi Freedom andOperation Enduring Freedom-era
veterans with co-occurring disorders of post-traumatic stress
disorder and opioid abuse; we had no other inclusion or
exclusion criteria. Opioid craving produces a more robust
physiologic response than craving for drugs such as cocaine
[5–9]. The focus group began with a broad description of
iHeal, its purpose, and general functionality. Open-ended
questions explored potential content; reflective listening,
and summative statements encouraged elaboration. The in-
terview then proceeded to explicit probes about the pre-
ferred location of sensor bands; the anticipated number of
acceptable interactions between iHeal and user per day; and
content for the annotation panel, such as intensity of drug
craving, assessments of affect/stress, and activities. Results
from our solicitation of user perspectives on materials
allowed us to improve study components in preparation
for the main study.
The mobile nature of the iHeal Project placed several
unanticipated constraints on the investigation. The Veterans
Administration (VA) assiduously protects the safety and con-
fidentiality of all its patients, especially those participating in
research investigations. Furthermore, recent security breaches
have led the VA to adopt stringent security measures on
mobile data storage devices. Although we intended to collect
only de-identified data, the possibility existed for study par-
ticipants to enter personal identifying information into other
embedded smartphone programs such as text message or
notetaking applications. We therefore encrypted all iHeal data
files to ensure patient confidentiality; we also reprogrammed
the smartphone to prevent data entry into other applications.
An additional complication was loss of de-identified partici-
pant data if the iHeal smartphone was lost or sold. Although
we conducted the study in a residential treatment center, we
nonetheless created a detailed protocol for VA and press
notification in the event a study device was lost.
Results
System Architecture The iHeal system architecture is pre-
sented in Fig. 1. Although multiple mobile computing plat-
forms exist, we elected to use smartphones running Android
OS 2.2 or later since this operating system supports the use
of multiple Bluetooth connections from the sensor band to
the phone. We selected Android over competitor operating
systems because of its ease of programming and the ability
to modify the appearance of the final product. Finally, the
system architecture included, in addition to the mobile
phone and sensor, a web server running on a desktop PC
and a Microsoft SQL database running on a secure server in
a high-security location. Software programmed into the
mobile phone allowed three separate means to interact with
the user: self-reported drug craving/stress initiated by the
user; a random assessment and annotation, the timing of
which was generated by the iHeal software; and an assess-
ment and annotation that is triggered by changes in the
user’s physiology.
Focus Group Seven male veterans (six Caucasian, one Af-
rican–American ages 27–55) undergoing residential treat-
ment participated in the focus group. All members had
substance abuse disorders including opioid abuse, as well
as post-traumatic stress disorder. Despite being homeless
and in treatment for problematic substance use, all participants
owned mobile phones with active service plans; three (42%)
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owned smartphones with touch screens. Those with smart-
phones indicated that they would never return to the use of flip
phones (also called “feature” phones) as the older devices
lacked desirable functionality. While they appreciated the
immediacy of contact of text-based messages, participants
found the potential for inadvertent misunderstandings between
individuals and elimination of personal contact as disadvan-
tages of text messages. Rather than receive text messages to
promote treatment protocols, participants reported that videos,
apps, games, calming songs, or other media would be preferred
methods for introducing behavioral interventions.
The sensors measuring skin conductance, pulse rate, and
acceleration that we presented to the focus group were about
the size of a half dollar coin and housed in a standard athletic
wristband. Focus group members indicated that while this
embodiment was acceptable for research purposes, wearing
it outside of a residential drug treatment center might attract
unwanted attention. The focus group therefore recommended
that a more robust and less stigmatizing version would be
necessary before the device could be worn in public. Specific
comments were to develop a waterproof version, a sensor
band that had the appearance and functionality of a wrist-
watch, or a sensor band that was worn on the ankle.
Discussion
Mobile health, also known as “mHealth,” is the use of
mobile computing devices to support patient health [10].
At present, most mHealth applications focus upon tracking
self-reported health indicators (e.g., weight) or the sharing
of information; via existing services such as 3/4 G networks,
patients can exchange information or seek support from
health-related usergroups [11]. While such interactivity
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may be useful among a group with a nonstigmatizing dis-
ease, hidden populations—such as persons who abuse illicit
drugs, have psychiatric conditions, or who are infected with
HIV—may not openly share information regarding their
condition. Stigmatized patients, who still receive much of
their care from face-to-face interactions with clinicians, may
therefore benefit from the emerging branch of mHealth
known as enabling technologies [12]. Enabling technologies
such as iHeal differ from existing healthcare applications in
that they may to incorporate biosensors that potentially
allow the delivery of healthcare precisely at the moment of
greatest need. The monitoring functions and ubiquitous
presence of enabling technologies can prevent rather than
manage poor health by truncating the adverse behaviors that
lead to many common, expensive, and intractable medical
conditions.
Because enabling technologies are intended to be a per-
vasive presence, developing usable interfaces with designers
and form factors tuned to user preferences are critically
important to their acceptance [12]. The several ways in
which a user can interact with iHeal (Fig. 2) place the
technology at risk of becoming an annoying pest. Accept-
ability, therefore, hinges on correct timing of interactions
between iHeal and its user, the skill with which iHeal
communicates, and how well interventions resonate with
the recipient. Our focus group results indicate that self-
identified interventions for drug craving are more acceptable
than the standard approach of using text message-based
content couched in cognitive behavioral theory that have
been developed by treatment experts. By extension, these
findings suggest that study designers should rely upon
recipients rather than “experts” to create intervention con-
tent that would be maximally effective at preventing relapse.
The use of customized interventions may seem an intuitive
strategy, but this approach in uncommon in behavioral sci-
ence research even though interventions self-selected by the
patient under treatment have been recognized as a potentially
valuable treatment for problematic substance use [13]. Fur-
thermore, the use of customized interventions dovetails well
with iHeal, which is designed to recognize physioaffective
states and apply an intervention early to disrupt the condi-
tioned responses through maximizing coping-self statements
and self-efficacy—the essence of cognitive behavioral theory.
Considering that wrist sensors have a long history in
physiometric research, are easy to manufacture, and are
contained in an unobtrusive housing, we were surprised by
the lack of enthusiasm for this form factor. The heightened
visibility created a potential for stigmatization that, in the
opinion of our focus group members, outweighed user con-
venience and contributed to their poor acceptance. Alternative
form factors such as sensors worn on the ankle carry some
disadvantages. First, electrodermal activity is highly depen-
dent on body location, and measurement of physiologic
responses at the ankle is poorly understood. Considerable
laboratory work to measure individuals’ responses to drug
use cues (e.g., material such as drug paraphernalia designed
to elicit a craving response) must therefore precede iHeal field
testing. Second, ankle sensors can simply fall off during
normal activity without the user’s knowledge, a drawback to
be confronted by improved sensor band design.
Cellular phones are prone to loss, and using smartphones
as mobile data storage devices increases the risk for losing
not only research data, but also personal information as well.
Although we adapted the smartphones’ functionality to
eliminate the possibility of storing personally identifiable
data, we incorporated several additional protections. First,
all smartphones required password entry before the device
would activate. Second, we limited potential hacking of the
wireless signal by using Bluetooth communications in non-
discoverable mode and by limiting the power output on
devices so that the effective communication range for sensor
was several meters. Finally, we encrypted files on study
computing devices by using cryptographic modules con-
forming to a FIPS 140–2 standard [14].
The iHeal smartphone represents a potential cash equiva-
lent to individuals with histories of drug abuse through theft
and subsequent sale. Even though we avoided this problem by
conducting our investigation in residential drug treatment, we
do not believe that the diversion of study devices to illicit sale
will occur since multiple NIDA-funded investigators have
provided cellphones and PDAs to active drug abusers who
participated in a demanding regimen of randomly timed inter-
ruptions [15, 16]. Participants were compensated for the
return of devices, a practice that prevented attrition of study
devices [15, 16].
This study demonstrates that conducting clinical trials
using enabling technologies in natural environments will
require a deeper understanding of user preferences. In par-
ticular, a focus on preventing identification of research
participants may prevent subsequent stigmatization. Techni-
cal issues related to data security that are well described
should be implemented to ensure the confidentiality and
anonymity of study participation. Finally, attrition of expen-
sive mobile data collection platforms such as smartphones
can be prevented through selection of study site as well as
remuneration for return of devices.
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